Congenital Stationary Night Blindness

Congenital Stationary Night Blindness (CSNB) is a rare, inherited eye condition that affects how the retina—the light-sensitive tissue at the back of the eye—processes light. People with CSNB have difficulty seeing in dark or dimly lit environments, a symptom known as night blindness, which is usually present from birth. In addition to poor night vision, individuals with CSNB often experience other eye issues, such as nearsightedness (myopia), involuntary eye movements (nystagmus), crossed eyes (strabismus), and reduced overall visual sharpness. The term "stationary" means that unlike some other genetic eye diseases, CSNB does not get worse over time. The vision problems a person has in childhood will generally remain stable throughout their life, and the condition does not lead to complete blindness. CSNB is caused by changes (mutations) in one of several genes responsible for sending visual signals from the eye to the brain. Because it is a genetic condition, it can be passed down through families in different ways. Currently, there is no cure for CSNB, but the symptoms can be managed to help individuals maximize their vision and maintain a good quality of life. Management typically involves wearing glasses or contact lenses to correct nearsightedness and using low-vision aids if needed. Regular eye exams are important to monitor vision and check for any complications related to high nearsightedness. Genetic counseling can also be very helpful for families to understand how the condition is inherited and what it means for future generations.

Condition category: Stationary Disorder

Prevalence: 1 in 30,000 to 1 in 50,000

Inheritance patterns: X-Linked, Autosomal Recessive, Autosomal Dominant

Age of onset: Birth to early childhood

Clinical overview: Congenital Stationary Night Blindness (CSNB) is a clinically and genetically heterogeneous group of rare, non-progressive inherited retinal disorders primarily characterized by impaired vision in dark or dim light conditions (nyctalopia). The condition is caused by defects in the rod photoreceptor phototransduction cascade, the visual cycle, or the synaptic transmission between photoreceptors and bipolar cells. CSNB is broadly classified into two main categories based on fundus appearance: those with normal fundi (which include the Riggs and Schubert-Bornschein types) and those with abnormal fundi (which include Fundus albipunctatus and Oguchi disease). The Schubert-Bornschein type is further subdivided into complete (cCSNB) and incomplete (iCSNB) forms based on electroretinogram (ERG) findings, which reflect specific deficits in the ON- and OFF-bipolar cell pathways. In addition to night blindness, patients frequently present with other ocular manifestations, including reduced visual acuity, high myopia, nystagmus, and strabismus. Unlike progressive retinal dystrophies such as Retinitis Pigmentosa, the retinal dysfunction in CSNB remains stable throughout life, and it does not typically lead to complete blindness. The clinical significance of CSNB lies in its complex genetic etiology and the necessity for precise diagnostic differentiation from progressive blinding diseases. Accurate diagnosis relies heavily on full-field ERG and molecular genetic testing. CSNB is associated with numerous OMIM entries reflecting its genetic diversity, including OMIM 310500 (X-linked cCSNB), OMIM 300071 (X-linked iCSNB), OMIM 163500 (Autosomal dominant CSNB), and OMIM 613216 (Autosomal recessive cCSNB), among others. The condition is also recognized under Orphanet number ORPHA:215. Understanding the specific subtype and genetic basis is crucial for providing appropriate genetic counseling, prognostic information, and targeted management for affected individuals and their families.

Patient and family guide: Congenital Stationary Night Blindness (CSNB) is a rare, inherited eye condition that affects how the retina—the light-sensitive tissue at the back of the eye—processes light. People with CSNB have difficulty seeing in dark or dimly lit environments, a symptom known as night blindness, which is usually present from birth. In addition to poor night vision, individuals with CSNB often experience other eye issues, such as nearsightedness (myopia), involuntary eye movements (nystagmus), crossed eyes (strabismus), and reduced overall visual sharpness. The term "stationary" means that unlike some other genetic eye diseases, CSNB does not get worse over time. The vision problems a person has in childhood will generally remain stable throughout their life, and the condition does not lead to complete blindness. CSNB is caused by changes (mutations) in one of several genes responsible for sending visual signals from the eye to the brain. Because it is a genetic condition, it can be passed down through families in different ways. Currently, there is no cure for CSNB, but the symptoms can be managed to help individuals maximize their vision and maintain a good quality of life. Management typically involves wearing glasses or contact lenses to correct nearsightedness and using low-vision aids if needed. Regular eye exams are important to monitor vision and check for any complications related to high nearsightedness. Genetic counseling can also be very helpful for families to understand how the condition is inherited and what it means for future generations.

Symptoms and clinical features: The clinical presentation of Congenital Stationary Night Blindness (CSNB) is characterized by symptoms that are present from birth or early childhood and remain stable throughout life. The hallmark symptom is nyctalopia, or night blindness, where patients experience significant difficulty seeing in dark or dimly lit environments. This symptom is often noticed in early childhood when a child struggles to navigate in the dark or exhibits fear of unlit spaces. In addition to nyctalopia, patients frequently present with reduced best-corrected visual acuity, which typically ranges from 20/30 to 20/200, depending on the specific subtype of the disease. Associated ocular features are common and often prompt the initial clinical evaluation. High myopia (nearsightedness) is a frequent finding, particularly in the Schubert-Bornschein subtypes, though hyperopia can also occur. Patients often exhibit nystagmus, which is typically described as a pendular, dysconjugate, oblique movement of high frequency and low amplitude. Strabismus (crossed eyes) is also frequently observed. In the complete subtype of CSNB, patients may additionally complain of photophobia (sensitivity to bright light), while color vision is generally preserved, though mild impairments can sometimes be detected in the incomplete subtype. Because CSNB is a non-progressive disorder, the symptoms do not typically worsen into intermediate or advanced stages as seen in progressive retinal dystrophies. The visual acuity, degree of night blindness, and associated features like nystagmus generally remain stable from childhood through adulthood. However, patients with high myopia are at an increased risk for secondary complications later in life, such as retinal detachment or myopic macular degeneration, which can cause acute or progressive vision loss independent of the underlying stationary retinal dysfunction. CSNB is typically an isolated ocular condition and is not associated with systemic syndromic features.

Molecular pathology: The molecular pathology of Congenital Stationary Night Blindness (CSNB) involves disruptions in the intricate processes of phototransduction, visual cycle retinoid recycling, or synaptic transmission between photoreceptors and bipolar cells. In Riggs-type CSNB, the defect lies within the rod photoreceptors themselves. Mutations in genes such as RHO (rhodopsin), GNAT1 (alpha subunit of rod transducin), and PDE6B (beta subunit of rod phosphodiesterase) impair the activation or regulation of the phototransduction cascade. This prevents rods from properly hyperpolarizing in response to light, leading to a failure in initiating the visual signal in dim light conditions. Schubert-Bornschein CSNB is characterized by defects in the synaptic transmission from photoreceptors to bipolar cells. In the complete subtype (cCSNB), mutations in genes like NYX (nyctalopin), TRPM1 (transient receptor potential cation channel subfamily M member 1), GRM6 (metabotropic glutamate receptor 6), GPR179, and LRIT3 disrupt the ON-bipolar cell signaling pathway. These proteins are essential for the proper localization and function of the signaling complex at the dendritic tips of ON-bipolar cells. When this complex is dysfunctional, the ON-bipolar cells fail to depolarize in response to the decrease in glutamate release from photoreceptors upon light stimulation, effectively blocking signal transmission. In the incomplete subtype (iCSNB), the defect is localized to the photoreceptor synapse. Mutations in CACNA1F (encoding the alpha-1F subunit of a voltage-gated calcium channel) or CABP4 (calcium-binding protein 4) impair the function of the presynaptic calcium channels in photoreceptor terminals. This disruption leads to abnormal calcium influx and subsequent dysregulation of continuous glutamate release in the dark, affecting signaling to both ON- and OFF-bipolar cells. Additionally, conditions like Fundus albipunctatus and Oguchi disease involve defects in the visual cycle (e.g., RDH5 mutations affecting 11-cis-retinol dehydrogenase) or the deactivation of phototransduction (e.g., SAG or GRK1 mutations), resulting in delayed dark adaptation and prolonged recovery of rod function.

Genetics: Congenital Stationary Night Blindness (CSNB) is a highly genetically heterogeneous disorder, with mutations identified in at least 17 different genes. The condition can be inherited in X-linked recessive, autosomal recessive, or autosomal dominant patterns, depending on the specific gene involved. X-linked CSNB is primarily caused by mutations in the NYX gene (complete CSNB) and the CACNA1F gene (incomplete CSNB). Autosomal recessive forms are associated with mutations in genes such as GRM6, TRPM1, GPR179, LRIT3, CABP4, CACNA2D4, SLC24A1, RDH5, GRK1, and SAG. Autosomal dominant inheritance is less common and is typically linked to mutations in the RHO, GNAT1, and PDE6B genes. Genotype-phenotype correlations are well-established in CSNB, particularly concerning electroretinogram (ERG) findings. Mutations in genes encoding proteins involved in the phototransduction cascade within rod photoreceptors (e.g., RHO, GNAT1, PDE6B, SLC24A1) generally result in Riggs-type CSNB, characterized by reduced a- and b-waves on scotopic ERG. Conversely, mutations in genes essential for signal transmission from photoreceptors to bipolar cells (e.g., NYX, TRPM1, GRM6, GPR179, LRIT3, CACNA1F, CABP4) lead to Schubert-Bornschein CSNB, which features a normal a-wave but a severely reduced b-wave (electronegative ERG). Specific subtypes with fundus abnormalities also have distinct genetic etiologies. Fundus albipunctatus is caused by autosomal recessive mutations in the RDH5 gene, which encodes an enzyme critical for the visual cycle and retinoid recycling. Oguchi disease is associated with autosomal recessive mutations in either the SAG (arrestin) or GRK1 (rhodopsin kinase) genes, both of which are involved in the deactivation of the phototransduction cascade. The extensive genetic heterogeneity underscores the necessity of molecular genetic testing for accurate diagnosis, subtyping, and genetic counseling.

Diagnostic evaluation: Clinical diagnosis of Congenital Stationary Night Blindness (CSNB) relies heavily on a comprehensive ophthalmic examination, including a detailed family history and specialized testing. Fundoscopy typically reveals a normal appearance in most subtypes, such as Riggs-type and Schubert-Bornschein CSNB, aside from common myopic changes. However, specific subtypes present with distinct fundus abnormalities: Fundus albipunctatus is characterized by scattered yellow-white dots in the posterior pole sparing the macula, while Oguchi disease exhibits the Mizuo-Nakamura phenomenon, where the fundus has a golden-yellow sheen that disappears after prolonged dark adaptation. Optical Coherence Tomography (OCT) is generally unremarkable and does not show specific structural abnormalities unique to CSNB. The hallmark diagnostic tool for CSNB is full-field electroretinography (ERG), which distinguishes the various subtypes based on specific functional deficits. In Riggs-type CSNB, the dark-adapted dim flash ERG is non-detectable, and the strong flash ERG shows reduced a- and b-waves, indicating a primary photoreceptor defect. Conversely, Schubert-Bornschein CSNB is characterized by a normal a-wave but a severely reduced b-wave (an electronegative waveform) on the dark-adapted strong flash ERG, reflecting a defect in signal transmission from photoreceptors to bipolar cells. The complete subtype (cCSNB) shows an absence of ON-bipolar cell function, while the incomplete subtype (iCSNB) exhibits residual but diminished ON- and OFF-bipolar cell responses. Genetic testing, including targeted gene panels or whole-exome sequencing, is essential to confirm the diagnosis, identify the specific inheritance pattern, and determine the causative mutation among the numerous genes associated with CSNB. Differential diagnosis must exclude progressive inherited retinal dystrophies such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA), which also present with nyctalopia but involve progressive photoreceptor degeneration and distinct ERG and fundus changes. Other conditions to consider include achromatopsia and X-linked retinoschisis, which can be differentiated through clinical presentation, ERG findings, and genetic analysis.

Differential diagnosis: Differential diagnosis of CSNB includes: (1) Retinitis pigmentosa (early) — progressive, abnormal fundus, bone spicule pigmentation. (2) Vitamin A deficiency — reversible, low serum retinol, associated with malabsorption. (3) Fundus albipunctatus — white dots at level of RPE, delayed dark adaptation but eventually normal. (4) Oguchi disease — Mizuo-Nakamura phenomenon (golden sheen that disappears after dark adaptation). (5) Choroidal sclerosis — visible choroidal vessels, progressive. (6) X-linked retinoschisis — macular schisis, negative ERG pattern similar to CSNB.

Natural history: Congenital Stationary Night Blindness (CSNB) is classically defined as a non-progressive retinal disorder, meaning that the visual deficits present at birth or in early childhood typically remain stable throughout the patient's life. The hallmark symptom, nyctalopia (night blindness), is usually present from birth, although it may not be recognized until the child is old enough to articulate visual difficulties in dim light or until parents notice behavioral signs, such as reluctance to navigate in the dark. Visual acuity in CSNB is often reduced, ranging from 20/30 to 20/200, and this impairment is generally stable. The degree of visual acuity reduction varies depending on the subtype, with the complete form of Schubert-Bornschein CSNB typically presenting with more severe visual impairment compared to the incomplete form. Associated ocular features, such as high myopia, nystagmus, and strabismus, are also typically present from an early age and do not show significant progressive worsening, although refractive errors require ongoing management. While the primary retinal dysfunction in CSNB is stationary, patients may experience secondary complications related to their high myopia, such as an increased risk of retinal detachment or myopic macular degeneration later in life. Therefore, while the underlying genetic defect does not cause progressive photoreceptor death as seen in conditions like Retinitis Pigmentosa, the long-term visual prognosis depends on the management of associated refractive errors and the monitoring of potential myopic complications.

Management and treatment research: ### Current management and standard of care There is currently no cure for congenital stationary night blindness (CSNB). Care focuses on maximizing vision, addressing associated eye conditions, and supporting safe daily activities. CSNB is generally non-progressive, meaning that symptoms usually do not worsen over time, although visual needs can vary by genetic type. Management may include: - **Correction of refractive errors:** Glasses or contact lenses can improve vision in people with myopia (nearsightedness), hyperopia (farsightedness), or astigmatism. Some forms of CSNB are associated with high myopia. - **Amblyopia and strabismus care:** Children with reduced vision in one eye (amblyopia) or eye misalignment (strabismus) may benefit from early assessment and treatment. This may include glasses, patching when appropriate, and care from a pediatric eye specialist. - **Low-vision and educational support:** Magnifiers, screen-accessibility tools, classroom accommodations, and orientation and mobility training may help people whose night vision, contrast sensitivity, or daytime vision affects school, work, or independence. - **Night-vision strategies:** Improving lighting, allowing time for the eyes to adapt when moving between bright and dim areas, and using extra caution with nighttime driving or unfamiliar low-light settings can be helpful. - **Monitoring high myopia:** People with high myopia should have regular dilated retinal examinations because high myopia increases the risk of retinal tears and retinal detachment. Genetic testing and genetic counseling can help confirm the diagnosis, identify the responsible gene, clarify inheritance, and inform family planning. ### Approved therapies There are no approved medicines, gene therapies, or other treatments that specifically correct the retinal signaling changes responsible for CSNB. ### Investigational therapies #### Gene-based research CSNB can result from changes in genes involved in retinal signaling, particularly communication between rod photoreceptors—which support vision in dim light—and other retinal cells. Because retinal structure may be relatively preserved in many forms of CSNB, gene-based approaches are of scientific interest. Laboratory and animal studies have explored gene replacement strategies for some inherited retinal conditions, often using adeno-associated virus (AAV) vectors. An AAV vector is a modified virus designed to deliver a working copy of a gene to retinal cells. However, there are currently no CSNB-specific gene therapy programs in the listed treatment pipeline. #### Medicines and other approaches There are currently no CSNB-specific investigational medicines or other treatment programs in the listed pipeline. ### Clinical trial participation No CSNB-specific treatment trials are currently listed in the available clinical-trial data. The **Inherited Retinal Degenerative Disease Registry** (**NCT02435940**) is recruiting. This is a registry study that may collect health, vision, and genetic information from people with inherited retinal diseases. It is not a treatment trial. Other listed studies are for conditions such as retinitis pigmentosa, Leber congenital amaurosis, or glaucoma and are not CSNB treatment studies. Genetic confirmation of the cause of CSNB may help individuals and families identify future research opportunities as they become available.

Outlook: The overall visual prognosis for individuals with Congenital Stationary Night Blindness (CSNB) is generally favorable compared to progressive inherited retinal diseases. Because the condition is stationary, the visual deficits—including nyctalopia and reduced visual acuity—typically remain stable throughout the patient's life and do not progress to complete blindness. Patients can expect their daytime vision to remain consistent with the levels established in early childhood, allowing for a stable and predictable visual experience. Quality of life considerations primarily revolve around managing the functional impacts of night blindness and associated refractive errors. Individuals may require accommodations for navigating in low-light environments and may face challenges with activities such as driving at night. The presence of high myopia necessitates regular ophthalmic monitoring to manage the risk of secondary complications, such as retinal detachment or myopic macular degeneration. With appropriate refractive correction, low-vision aids if necessary, and supportive care, most individuals with CSNB can lead independent and fulfilling lives.

Epidemiology: The exact prevalence of Congenital Stationary Night Blindness (CSNB) is unknown, but it is considered a rare genetic disorder. Estimates suggest a prevalence of approximately 1 in 70,000 live births. The condition exhibits significant genetic heterogeneity, with the incomplete X-linked form being more commonly reported than the complete form. CSNB affects individuals across various geographic and ethnic populations, though specific founder mutations may lead to higher frequencies in certain isolated groups. Because the X-linked recessive forms (associated with the NYX and CACNA1F genes) are among the most common causes, males are disproportionately affected by these specific subtypes, while females are typically asymptomatic carriers. Autosomal dominant and autosomal recessive forms affect both males and females equally.

Selected references: 1. Kim AH, Liu PK, Chang YH, et al. Congenital Stationary Night Blindness: Clinical and Genetic Features. Int J Mol Sci. 2022;23(23):14965. PMID: 36499293 2. Zeitz C, Robson AG, Audo I. Congenital stationary night blindness: An analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res. 2015;45:58-110. PMID: 25307992 3. Katta M, et al. Congenital Stationary Night Blindness: Structure, Function, and Progression. Ophthalmology Retina. 2024. 4. Tsang SH, Sharma T. Congenital Stationary Night Blindness. Adv Exp Med Biol. 2018;1085:61-64. PMID: 30578485 5. Bijveld MM, Florijn RJ, Bergen AA, et al. Genotype and phenotype of 101 Dutch patients with congenital stationary night blindness. Ophthalmology. 2013;120:2072-2081. PMID: 23714322